http://www.sciclone.com

Foster City, CA — 

SciClone (NASDAQ: SCLN) is a revenue-generating, profitable, China-centric specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.  SciClone acquired Atlas portfolio company Novamed in April 2011.